Cross-reactive humoral responses to influenza and their implications for a universal vaccine

Annals of the New York Academy of Sciences

Volumn 1283, Issue 1, 2013, Pages 13-21

  Chiu, Christopher ^a,b   Wrammert, Jens ^a   Li, Gui Mei ^a   Mccausland, Megan ^a   Wilson, Patrick C ^c   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antibodies; B cells; Hemagglutinin; Influenza; Stem; Vaccination

Indexed keywords

CROSS REACTING ANTIBODY; HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

2009 H1N1 INFLUENZA; ARTICLE; CROSS REACTION; DRUG EFFICACY; GENETIC REASSORTMENT; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; INFLUENZA VACCINATION; PANDEMIC INFLUENZA; SEASONAL INFLUENZA; VIRUS STRAIN;

EID: 84876791705     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12012     Document Type: Article

References (38)

1. Thompson, W. et al. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
2. Molinari, N.A. et al. 2007. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25: 5086-5096.
3. Fields, B.N., D.M. Knipe & P.M. Howley . 2007. Fields' Virology. Wolters Kluwer/Lippincott Williams & Wilkins: Philadelphia, PA, London.
4. Skehel, J.J. & D.C. Wiley . 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69: 531-569.
5. Mitnaul, L.J. et al. 2000. Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J. Virol. 74: 6015-6020.
6. Ellebedy, A.H. & R.J. Webby . 2009. Influenza vaccines. Vaccine 27: D65-D68.
7. Ward, C.W. 1981. Structure of the influenza virus hemagglutinin. Curr. Top. Microbiol. Immunol. 94-95: 1-74.
8. Caton, A.J., G.G. Brownlee, J.W. Yewdell & W. Gerhard . 1982. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31: 417-427.
9. Wiley, D.C., I.A. Wilson & J.J. Skehel . 1981. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289: 373-378.
10. Wilson, I.A. & N.J. Cox . 1990. Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 8: 737-787.
11. Nabel, G.J. & A.S. Fauci . 2010. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16: 1389-1391.
12. Sui, J. et al. 2011. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis. 52: 1003-1009.
13. Yewdell, J.W., R.G. Webster & W.U. Gerhard . 1979. Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule. Nature 279: 246-248.
14. Garten, R.J. et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
15. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team et al. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360: 2605-2615.
16. Subbarao, K. et al. 1998. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279: 393-396.
17. Osterholm, M.T., N.S. Kelley, A. Sommer & E.A. Belongia . 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12: 36-44.
18. Ambrose, C.S., M.J. Levin & R.B. Belshe . 2011. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir. Viruses 5: 67-75.
19. Wright, P.F. et al. 2008. Antibody responses after inactivated influenza vaccine in young children. Pediatr. Infect. Dis. J. 27: 1004-1008.
20. Hannoun, C., F. Megas & J. Piercy . 2004. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 103: 133-138.
21. Monto, A.S. et al. 2009. Comparative efficacy of inactivated and live attenuated influenza vaccines. N. Engl. J. Med. 361: 1260-1267.
22. Wrammert, J. et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671.
23. Smith, K. et al. 2009. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nature Protocols 4: 372-384.
24. Wrammert, J. et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208: 181.
25. Okuno, Y., Y. Isegawa, F. Sasao & S. Ueda . 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67: 2552-2558.
26. Throsby, M. et al. 2008. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
27. Ekiert, D.C. et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
28. Sui, J. et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16: 265-273.
29. Corti, D. et al. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120: 1663-1673.
30. Dreyfus, C. et al. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348.
31. Calder, L.J., S. Wasilewski, J.A. Berriman & P.B. Rosenthal . 2010. Structural organization of a filamentous influenza A virus. Proc. Natl. Acad. Sci. USA 107: 10685-10690.
32. Harris, A. et al. 2006. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc. Natl. Acad. Sci. USA 103: 19123-19127.
33. Li, G.-M. et al. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. PNAS 109: 9047-9052.
34. Corti, D. et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
35. Sasaki, S. et al. 2006. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J. Virol. 81: 215-228.
36. Kreijtz, J.H.C.M., R.A.M. Fouchier & G.F. Rimmelzwaan . 2011. Immune responses to influenza virus infection. Virus Res. 162: 19-30.
37. Steel, J. et al. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio pii: e00018-10. doi: 10.1128/mBio.00018-10.
38. Khurana, S. et al. 2011. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3: 85ra48.